SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced that preclinical data from its lead candidate, CID-078, a first-in-class oral macrocycle cyclin A/B RxL inhibitor, has been selected for a late-breaking poster presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, also known as the Triple Meeting.

加利福尼亚州南旧金山——（商业新闻短讯）——Circle Pharma是一家致力于发现和开发新一代大环疗法的临床阶段生物制药公司，今天宣布，其主要候选人CID-078（一种一流的口服大环素a/B RxL抑制剂）的临床前数据已被选为第36届EORTC-NCI-AACR分子靶标和癌症治疗研讨会（也称为三重会议）的最新海报展示。

The symposium is taking place from October 23-25, 2024, in Barcelona, Spain..

研讨会于2024年10月23日至25日在西班牙巴塞罗那举行。。

Poster presentation details are below:

海报展示详情如下：

Author: Wang et al.

作者：王等人。

Title: CID-078, a First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, Demonstrates Anti-Tumor Activity in ESF-driven Cancers

标题：CID-078是一种一流的口服大环细胞周期蛋白a/B RxL抑制剂，在ESF驱动的癌症中显示出抗肿瘤活性

Abstract Number: PB-515

摘要编号：PB-515

Session Title: Late breaking posters

课程名称：迟发海报

Date and Time: October 23, 2024 (6 a.m. EST/12 p.m. CEST) to October 25, 2024 (11 a.m. EST/5 p.m. CEST)

日期和时间：2024年10月23日（美国东部时间上午6点/CEST下午12点）至2024年12月25日（美国东部时间上午11点/CEST下午5点）

The digital poster can be viewed here.

可以在此处查看数字海报。

The pre-clinical data shows CID-078 demonstrated single-agent tumor activity across tumor cell line and in vivo models with dysregulated cell cycle (CDK-RB-E2F) function. Notably, tumor regressions were observed in small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC) preclinical models.

临床前数据显示CID-078在肿瘤细胞系和具有失调细胞周期（CDK-RB-E2F）功能的体内模型中表现出单药肿瘤活性。值得注意的是，在小细胞肺癌（SCLC），非小细胞肺癌（NSCLC）和三阴性乳腺癌（TNBC）临床前模型中观察到肿瘤消退。

Within specific indications, CID-078 single agent activity was correlated with RB1 mutation, high E2F target, or G2M checkpoint hallmark pathway scores. The cumulative pre-clinical data suggests that CID-078 holds promise as a monotherapy for patients with these cancers. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients..

在特定适应症内，CID-078单药活性与RB1突变，高E2F靶标或G2M检查点标志性途径评分相关。累积的临床前数据表明，CID-078有望成为这些癌症患者的单一疗法。目前，一项多中心1期临床试验（NCT06577987）正在招募患者。。

About CID-078

关于CID-078

CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma’s cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B).

CID-078是一种口服生物可利用的大环化合物，具有双重细胞周期蛋白A和B RxL抑制活性，可选择性靶向具有致癌改变的肿瘤细胞，从而导致细胞周期失调。在生化和细胞研究中，Circle Pharma的细胞周期蛋白A/B RxL抑制剂已被证明可以有效和选择性地破坏细胞周期蛋白A和B与其关键底物和调节剂（包括E2F（细胞周期蛋白A的底物））之间的蛋白质相互作用。和Myt1（细胞周期蛋白B的调节剂）。

Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients..

临床前研究已经证明这些细胞周期蛋白A/B RxL抑制剂在多种体内模型中引起单药肿瘤消退的能力。目前，一项多中心1期临床试验（NCT06577987）正在招募患者。。

About Circle Pharma, Inc.

关于Circle Pharma，Inc。

South San Francisco-based Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs.

总部位于南旧金山的Circle Pharma正在推进本质上可渗透细胞的大环化合物的发现和开发，这些大环化合物可以通过多种途径递送，包括口服给药。Circle Pharma的MXMO™平台结合了基于结构的合理药物设计和先进的合成化学，开发了新一代大环疗法，以应对挑战性目标，以满足未满足的临床需求。

Circle Pharma is focusing its development efforts on cyclins, which are master regulators of the machinery that controls the progression of cells through the cell cycle and are key drivers in many cancers..

Circle Pharma将其开发工作重点放在细胞周期蛋白上，细胞周期蛋白是控制细胞在细胞周期中进展的主要调节因子，也是许多癌症的关键驱动因素。。

To learn more about Circle Pharma, please visit www.circlepharma.com.

欲了解更多有关Circle Pharma的信息，请访问www.circlepharma.com。